Conivaptan, sold under the brand name Vaprisol, is a non-peptide inhibitor of the receptor for anti-diuretic hormone, also called vasopressin. It was approved in 2004 for hyponatremia (low blood sodium levels). Additionally, conivaptan is used for the tre + some more technical info — conivaptan is an intravenous, non-selective vasopressin receptor antagonist with activity at V1A and V2 receptors that produces aquaresis by blocking renal V2 mediated water reabsorption and can also modulate vascular tone via V1A antagonism; it is indicated for acute euvolemic and hypervolemic hyponatremia in hospitalized patients, is administered as an IV bolus followed by continuous infusion, undergoes hepatic metabolism with clinically relevant CYP3A interactions, and requires monitoring of serum sodium and volume status during therapy.
Typical quality control specifications for conivaptan drug substance and finished product focus on related substances and degradation products detected by validated chromatographic methods such as HPLC and LC MS. Pharmacopeial and regulatory practice commonly controls individual known related compounds at low parts per hundred or parts per thousand levels, for example individual impurities typically are limited to 0.05 to 0.20 percent relative to the API peak area depending on impurity identity and toxicological risk, with total known and unknown impurities commonly limited to 0.5 to 1.0 percent; genotoxic or structurally alerting impurities are controlled to much lower thresholds in line with ICH M7 guidance. Commonly observed related compounds for this class include N dealkylated, desmethyl, hydroxylated and N oxide species as well as process- and storage related degradants, and these are identified, quantified and qualified during stability and impurity profiling.
Conivaptan is used intravenously to treat hospitalized patients with clinically significant euvolemic or hypervolemic hyponatremia, including cases due to the syndrome of inappropriate antidiuretic hormone secretion, by promoting aquaresis and increasing serum sodium under close monitoring.
Tolvaptan is an oral, selective V2 receptor antagonist primarily used for chronic management of hyponatremia and for slowing progression of autosomal dominant polycystic kidney disease, whereas conivaptan is an intravenous, non selective vasopressin antagonist with activity at both V1A and V2 receptors used for acute inpatient correction of hyponatremia and associated with significant CYP3A mediated interactions.
Yes, conivaptan can be used to treat hyponatremia caused by SIADH in hospitalized patients when rapid correction of sodium is needed and fluid restriction is ineffective, but it should be used with careful monitoring of serum sodium, fluid balance and potential drug interactions.
Yes, conivaptan increases free water excretion, producing an aquaretic effect that raises urine volume without proportionate sodium loss, which leads to a rise in serum sodium; patients should be monitored for changes in urine output and sodium to avoid overly rapid correction.
